Polypoidal choroidal vasculopathy: natural history11InternetAdvance publication at ajo.com April 15, 2002.

Uyama, M; Wada, Mitsumasa; Nagai, Yoshimi; Matsubara, Takashi; Matsunaga, Hiroshi; Fukushima, Ichiro; Takahashi, Kanji; Matsumura, Miyo

doi:10.1016/s0002-9394(02)01404-6

Cited by 381 publications

(120 citation statements)

References 23 publications

Supporting

Mentioning

114

Contrasting

Order By: Relevance

“…The latter is usually active and tends to cause hemorrhage or leakage, followed by visual loss [28]. Of the 7 patients identified as having the clustered polyp type, only 1 patient showed a poor response to intravitreal bevacizumab and a >10% increase in CRT at 3 months, whereas the other 6 showed a >10% improvement in CRT compared with baseline.…”

Section: Discussionmentioning

confidence: 99%

Short-Term Safety and Efficacy of a Single Intravitreal Bevacizumab Injection for the Management of Polypoidal Choroidal Vasculopathy

et al. 2008

View full text Add to dashboard Cite

Aims: To evaluate the short-term safety and efficacy of a single intravitreal bevacizumab injection in patients with polypoidal choroidal vasculopathy (PCV). Methods: The records of patients treated with intravitreal bevacizumab for PCV were retrospectively reviewed. All patients were evaluated by complete ophthalmic examination, optical coherence tomography and fluorescein and indocyanine green angiography. Changes in visual acuity and central retinal thickness (CRT) over 3 months were the main outcome measures. Results: Nineteen eyes of 18 patients were included. No serious ocular or systemic adverse events were observed. The median baseline visual acuity and CRT were 20/100 and 230 μm, respectively. After 1 month, there was no significant improvement in median visual acuity (20/80⁺¹; p = 0.055), but median CRT had decreased significantly (160 μm; p < 0.001). After 3 months (data available for 17 eyes), both median visual acuity (20/63^–2; p = 0.001) and CRT (190 μm; p = 0.007) showed significant improvements over baseline values. Conclusions: Intravitreal bevacizumab therapy for PCV was well tolerated over the 3-month follow-up period. Short-term results are promising, but further studies are necessary to evaluate long-term efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Short-Term Safety and Efficacy of a Single Intravitreal Bevacizumab Injection for the Management of Polypoidal Choroidal Vasculopathy

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Uyama et al [10]classified PCV into exudative and hemorrhagic patterns and explained that the rupture of polypoid elements would lead to hemorrhage. It is surprising that such hemorrhage may occur after PDT, considering that PDT easily closes these polyps.…”

Section: Discussionmentioning

confidence: 99%

“…The pathogenesis of PCV is unclear, and its natural course is not well characterized. Uyama et al [10]reported that 50% of patients experience an unfavorable course, and that a cluster of grapelike polypoid lesions poses risks such as bleeding and leakage.…”

Section: Introductionmentioning

confidence: 99%

Photodynamic Therapy with Verteporfin for Polypoidal Choroidal Vasculopathy of the Macula

et al. 2004

View full text Add to dashboard Cite

Purpose: Indications for photodynamic therapy (PDT) have increased from age-related macular degeneration with choroidal neovascularization (CNV), containing more than 50% of the classic component, to occult CNV, myopic CNV and CNV due to ocular histoplasmosis syndrome. In the present study, the effect of PDT with verteporfin was examined in polypoidal choroidal vasculopathy (PCV) of the macula. Methods: PDT was performed in 9 eyes with PCV of the macula. Fundus examination, fluorescein angiography, and indocyanine green angiography were performed before PDT and 3 months after PDT in all eyes. Optical coherence tomography was performed in 6 eyes. Results: After the initial PDT, visual acuity was stabilized or improved in 8 eyes (89%), polypoid elements were obliterated in 7 eyes (78%), and vascular nets were reduced in 8 eyes (89%). Of 6 eyes that received optical coherence tomography, pigment epithelium detachment was reduced or disappeared in all eyes except 1, which developed a disciform scar. An additional PDT was performed in 4 eyes to decrease vascular leakage. During the follow-up period of 3–18 months, no reactivation of PCV was observed. Conclusion: PDT offers an effective way of treating PCV of the macula, by obliterating polypoid elements of the PCV. However, long-term follow-up is needed.

show abstract

“…In a separate Japanese study, 58.5% of 164 eyes with neovascular AMD and RPE detachment were found to have PCV features [10]. PCV is also reported to occur in 8–13% of Caucasian patients presenting with a diagnosis of neovascular AMD [9,10,11,12]. …”

Section: Introductionmentioning

confidence: 99%

“…It is widely believed that PCV has a relatively benign long-term visual prognosis when compared to typical AMD [1,4,5,6,7,8,9, 12]; however, specific documentation of such a benign course in large-scale studies is lacking. In one natural history study of 12 Japanese PCV patients, 50% were found to have a favorable visual outcome at 2 years [12]. Other Japanese investigators have noted that PCV eyes have a low rate of subretinal fibrovascular proliferation, slow progression of the vascular abnormality and infrequent formation of classic CNV [8].…”

Section: Introductionmentioning

confidence: 99%

Clinical Features of Polypoidal Choroidal Vasculopathy and Visual Outcomes in the Absence of Classic Choroidal Neovascularization

Yamaoka¹,

Okada²,

Sugahara³

et al. 2009

Ophthalmologica

View full text Add to dashboard Cite

Background/Aims: To report on the clinical features of polypoidal choroidal vasculopathy (PCV) and to delineate visual outcomes in the absence of classic choroidal neovascularization (CNV). Methods: Records were retrospectively reviewed of 233 eyes of 215 patients diagnosed with ‘definite’ PCV using Japanese criteria. Results: Of patients with definite PCV, 72.1% were men and 91.6% had unilateral disease. A history of systemic hypertension was elicited in 18.1% of patients, and blood pressure measurement revealed possible hypertension in 27.4% of patients. At the initial evaluation, 28.3% of eyes had classic CNV as assessed by fluorescein angiography and were treated by photodynamic therapy or other means. Of 112 eyes with active exudation but no classic CNV and no recent decreased vision, best-corrected visual acuity (BCVA) at 3 months improved by ≧0.2 logarithm of the minimum angle of resolution (logMAR) in 17%, was unchanged in 72% and worsened by ≧0.2 logMAR in 11%. In 67 eyes of which 1-year data were available, BCVA improved in 19%, was unchanged in 64% and worsened in 16%. Conclusions: The majority of PCV patients were men, with a high rate of diagnosed or suspected hypertension. More than two thirds of eyes had no evidence of classic CNV, of which 89% had stable or improved vision at 3 months without specific treatment. Of eyes followed for 12 months, 83% had stable or improved vision.

show abstract

Polypoidal choroidal vasculopathy: natural history11InternetAdvance publication at ajo.com April 15, 2002.

Cited by 381 publications

References 23 publications

Short-Term Safety and Efficacy of a Single Intravitreal Bevacizumab Injection for the Management of Polypoidal Choroidal Vasculopathy

Short-Term Safety and Efficacy of a Single Intravitreal Bevacizumab Injection for the Management of Polypoidal Choroidal Vasculopathy

Photodynamic Therapy with Verteporfin for Polypoidal Choroidal Vasculopathy of the Macula

Clinical Features of Polypoidal Choroidal Vasculopathy and Visual Outcomes in the Absence of Classic Choroidal Neovascularization

Contact Info

Product

Resources

About